Molecular & Cellular Proteomics · 2008 · 115 citations · 60 references
Life SciencesMolecular BiologyOncologyApoptosisMolecular OncologyProteomicsCancer BiomarkersCancer ProteomicsEndometrial CancerMolecular Tumor ProfilingProteomic BiomarkersProteomic ProfilingGel ElectrophoresisPrognostic Marker AssessmentPrognostic VariablesTherapeutic Target IdentificationTumor ProteomicsTwo-dimensional ElectrophoresisTwo-dimensional Gel ElectrophoresisWestern Blot Analysis
Endometrial carcinoma is one of the most common malignancies of the female genital tract, and there is an urgent need for discovery of novel factors for prognostic assessment and therapeutic targets to endometrial carcinoma. Herein a two-dimensional gel electrophoresis and MALDI-Q-TOF MS/MS-based proteomics approach was used to identify differentially expressed proteins in endometrial carcinoma. Of the 99 proteins identified, cyclophilin A was one of the most significantly altered proteins, and its overexpression was confirmed using RT-PCR and Western blot analyses. Immunohistochemistry suggested a link between cyclophilin A expression and poor differentiation and decreased survival (p < 0.01). Knockdown of cyclophilin A expression by RNA interference led to the significant suppression of the cell growth and the induction of apoptosis in endometrial carcinoma HEC-1-B cells in vitro (p < 0.01) and the inhibition of tumor growth in vivo (p < 0.01). These data suggest that cyclophilin A may serve as a novel prognostic factor and possibly an attractive therapeutic target for endometrial carcinoma. Endometrial carcinoma is one of the most common malignancies of the female genital tract, and there is an urgent need for discovery of novel factors for prognostic assessment and therapeutic targets to endometrial carcinoma. Herein a two-dimensional gel electrophoresis and MALDI-Q-TOF MS/MS-based proteomics approach was used to identify differentially expressed proteins in endometrial carcinoma. Of the 99 proteins identified, cyclophilin A was one of the most significantly altered proteins, and its overexpression was confirmed using RT-PCR and Western blot analyses. Immunohistochemistry suggested a link between cyclophilin A expression and poor differentiation and decreased survival (p < 0.01). Knockdown of cyclophilin A expression by RNA interference led to the significant suppression of the cell growth and the induction of apoptosis in endometrial carcinoma HEC-1-B cells in vitro (p < 0.01) and the inhibition of tumor growth in vivo (p < 0.01). These data suggest that cyclophilin A may serve as a novel prognostic factor and possibly an attractive therapeutic target for endometrial carcinoma. Endometrial carcinoma is one of the most common malignancies of the female genital tract with an approximately 80% 5-year survival for all stages taken together. Annually over 142,000 new cases develop worldwide, and an estimated 42,000 women die from this disease. The incidence of endometrial carcinoma varies among regions; it is 10 times higher in North America and European countries compared with developing countries (1Parkin D.M. Pisani P. Ferlay J. Global cancer statistics.CA Cancer. J. Clin. 1999; 49: 33-64Crossref PubMed Scopus (1843) Google Scholar). Recent studies have revealed that endometrial carcinoma is characterized by multiple pathogenetic steps and various genetic and epigenetic interactions (2Shiozawa T. Konishi I. Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment.Int. J. Clin. Oncol. 2006; 11: 13-21Crossref PubMed Scopus (30) Google Scholar,3Ioachin E. Immunohistochemical tumour markers in endometrial carcinoma.Eur. J. Gynaecol. Oncol. 2005; 26: 363-371PubMed Google Scholar). A wide variety of genetic molecules characterize the initiation, development, and outcome of this disease, including DNA methylation (4Shih M.C. Yeh K.T. Tang K.P. Chen J.C. Chang J.G. Promoter methylation in circadian genes of endometrial cancers detected by methylation-specific PCR.Mol. Carcinog. 2006; 45: 732-740Crossref PubMed Scopus (69) Google Scholar,5Helmle K.E. Otto C.J. Constantinescu G. Honore L.H. Andrew S.E. Variable MLH1 promotor methylation patterns in endometrial carcinomas of endometrioid subtype lacking DNA mismatch repair.Int. J. Gynecol. Cancer. 2005; 15: 1089-1096Crossref PubMed Scopus (9) Google Scholar) and altered expression or mutation of p53 (6Ragni N. Ferrero S. Prefumo F. Muschiato B. Gorlero F. Gualco M. Fulchen E. The association between p53 expression, stage and histological features in endometrial cancer.Eur. J. Obstet. Gynecol. Reprod. Biol. 2005; 123: 111-116Abstract Full Text Full Text PDF PubMed Scopus (21) Google Scholar), K-ras (7Tu Z. Gui L. Wang J. Li X. Sun P. Wei L. Tumorigenesis of K-ras mutation in human endometrial carcinoma via upregulation of estrogen receptor.Gynecol. Oncol. 2006; 101: 274-279Abstract Full Text Full Text PDF PubMed Scopus (21) Google Scholar), and BRAF (8Pappa K.I. Choleza M. Markaki S. Giannikaki E. Kyroudi A. Vlachos G. Voulgaris Z. Anagnou N.P. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status.Gynecol. Oncol. 2006; 100: 596-600Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar,9Feng Y.Z. Shiozawa T. Miyamoto T. Kashima H. Kurai M. Suzuki A. Konishi I. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression.Clin. Cancer Res. 2005; 11: 6133-6138Crossref PubMed Scopus (72) Google Scholar). Global gene expression analyses have been used to investigate the changes associated with this process (10Konstantakopoulos N. Montgomery K.G. Chamberlain N. Quinn M.A. Baker M.S. Rice G.E. Georgiou H.M. Campbell I.G. Changes in gene expressions elicited by physiological concentrations of genistein on human endometrial cancer cells.Mol. Carcinog. 2006; 45: 752-763Crossref PubMed Scopus (18) Google Scholar), including DNA microarray-based approaches for screening genes relevant to carcinogenesis (11Okada H. Nakajima T. Yoshimura T. Yasuda K. Kanzaki H. Microarray analysis of genes controlled by progesterone in human endometrial stromal cells in vitro.Gynecol. Endocrinol. 2003; 17: 271-280Crossref PubMed Scopus (40) Google Scholar,12Abal M. Planaguma J. Gil-Mireno A. Monge M. Gonzalez M. Baro T. Garcia A. Castellvi J. Ramon-Y-Cajal S. Xercavins J. Alameda F. Reventos J. Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors.Histol. Histopathol. 2006; 21: 197-204PubMed Google Scholar). Many novel markers, such as CD171 (13Fogel M. Huszar M. Altevogt P. Ben A.A. L1 (CD171) as a novel biomarker for ovarian and endometrial carcinomas.Expert Rev. Mol. Diagn. 2004; 4: 455-462Crossref PubMed Scopus (16) Google Scholar), PTEN (14Uegaki K. Kanamori Y. Kigawa J. Kawaguchi W. Kaneko R. Naniwa J. Takahashi M. Shimada M. Oishi T. Itomochi H. Terakawa N. PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma.Oncol. Rep. 2005; 14: 389-392PubMed Google Scholar), and urokinase plasminogen activator receptor (15Memarzadeh S. Kozak K.R. Chang L. Natarajan S. P. R. plasminogen activator prognostic biomarker for endometrial S. A. PubMed Scopus Google Scholar), have been and have been in diagnosis, and subtype the is that of of for endometrial carcinoma patients an urgent and need for of the molecular the of endometrial carcinoma. it in to the genetic and epigenetic there factors to molecular changes in and in tumor and and factors detected by the of RNA or by is that the association between protein and by analysis of the cancer or J.C. Rev. PubMed Scopus Google Scholar). A proteomics approach been with in the studies of of including and cancers and was to to of approaches for the of the molecular of endometrial carcinoma. a proteomics studies on endometrial carcinoma have been of the have been J. G. L. expression of endometrial malignancies a new tumor Res. 2004; PubMed Scopus Google T. T. R. Y. H. K. M. Y. Y. protein expression in endometrial 2005; PubMed Scopus Google L. G. J. for cancer markers from endometrial using and with and Res. 2005; 4: PubMed Scopus Google Scholar). These studies and the to among patients or such as of to identify a The of the was to identify novel molecules for or molecular therapeutic targets using a used endometrial cell analysis of molecular cell differentially expressed proteins revealed between carcinoma and and 99 proteins by Of cyclophilin A was characterized on the that it was to have an in for cancer Wang B. M.C. expression factor and cyclophilin A as molecular targets in cell Res. 2003; Google H. Chen J. J. S. S. L. A is in cell cancer and Res. PubMed Scopus Google Scholar) and cancer J. J. Li expression in compared with and by as detected by two-dimensional gel electrophoresis and Res. 2004; PubMed Scopus Google K. Y. S. M. S. M. K. K. I. K. of is in as by by two-dimensional electrophoresis and J. Oncol. Google Scholar). The data in this that cyclophilin A may a novel prognostic factor as as a therapeutic target for the of endometrial carcinoma. endometrial carcinoma and from patients from endometrial cancer the of of from to endometrial carcinoma from patients from to of endometrial carcinoma was to the by the in and was to the of the of and endometrial from patients from patients with for cases in the and cases in the taken by and and by for histological A of for patients is in features of all in in in or in in a new was by the of from all patients to in and in by and the was with The was in was using on a a of was for The for and and using a The protein in by analysis was using was by of of the by the of of one to the and expressed as a with < or changes in expression and higher for of and to the with the gel with of for and in for the with 10 of 10 for and with of The was and and with of by for all and in a using and in of of the was with an of on the target and to MALDI-Q-TOF was on a The was with an of a been from a of 10 of for and The of was between and on the of the from the as by the with the the for protein The data the of the with the as of to one and of and of The of the used was < the the for and on and over with significant the on the of proteins in the or the one protein to the H. with the was from a protein The and the of as cyclophilin and and RNA was using and RT-PCR was with as for and for for for or for and for and a for 10 and a stage in and in to to and with cyclophilin A The with and by The by the to the used cyclophilin A and cells with cyclophilin A a of with carcinoma and carcinoma cells for for or of cells was taken over The was as Y.Z. Shiozawa T. Miyamoto T. Kashima H. Kurai M. Suzuki A. J. Konishi I. of molecules and its in the of endometrial carcinoma Cancer Res. PubMed Scopus Google Scholar) with was as of and the of cells was as and The for was as A and the was as and The was using as A of for was by of and between the was by and was A cyclophilin A with the was to the of human cyclophilin A to been used in a S. M. I. T. of by and cyclophilin Res. 2004; PubMed Scopus Google Scholar) and to and used as a and used as for to the of cyclophilin to to The with to human was used as The a gene was with and and the a using DNA and by and using of the was confirmed by with and DNA from was and for the been a of DNA was and or The human endometrial carcinoma HEC-1-B cell was in The and in and a of The the cells in the concentrations to the on in with various for the was for The was in of and the was a cells with in in a and for with and a A with cells was as a cells on an was with a of cell and apoptosis with was to the The cells a and a with was as a The and of all studies female of and with HEC-1-B cells of via the the tumor the for The as of of of of and tumor to the tumor The of and the and of the for the The in and in and with and to data as between by among multiple by significant or of data between by and analysis of data was by to the and the analyses using analyses with was as < electrophoresis was with endometrial carcinoma and from patients analysis was using and and protein for human endometrial carcinoma and endometrial for endometrial carcinoma and a of and of and expressed proteins as significant on < and times in the to and using MALDI-Q-TOF A of 99 proteins from the of a protein have J. R. T. analysis of protein 2006; Full Text Full Text PDF PubMed Scopus Google Scholar), was to a protein for analysis in Of the of 99 in and most of been to in altered including cell protein and cell and apoptosis and from significantly altered proteins, times in the of in and expression in the of proteins with multiple for proteins with multiple a to the H. with the was X. L. L. J. Sun Z. J. analysis of cells with Full Text Full Text PDF PubMed Scopus Google Scholar). the and to that of the of characterized differentially expressed proteins times of the of proteins, a in the taken from the molecular of between endometrial carcinoma or endometrial carcinoma was using in endometrial protein protein protein in endometrial protein protein proteins, a in the taken from the of between endometrial carcinoma or endometrial carcinoma was using in a new A was to one of the most significant in expression between carcinoma and (p was in endometrial carcinoma compared with the and analysis revealed with and a of as in the altered expression of cyclophilin A in endometrial a was to its by RT-PCR A significant in the of cyclophilin A was between carcinoma and < 0.01). Western blot analysis was using A and overexpression of cyclophilin A was in all the carcinoma < 0.01) data that cyclophilin A is in endometrial carcinoma the and protein this is with the in the investigate the of cyclophilin A in endometrial carcinoma and to its and therapeutic was by of the cyclophilin A expression in of cyclophilin A to the and of the carcinoma cells revealed that the carcinoma cells for the overexpression of cyclophilin A and that this was to the in the was detected in of was detected in of and or was was detected in of was detected in of and was detected in of carcinoma was detected in of was detected in of and was detected in of in significant in and cells among and endometrial carcinoma < 0.01). in the of by a The for and carcinoma and suggested of cyclophilin A among and carcinoma < of endometrial carcinoma to cyclophilin A cyclophilin A in and endometrial < < < < < in a new by the in of the carcinoma and in stage in stage and in stage to by the of and in of the to the overexpression of cyclophilin A by is in of cyclophilin A was to significantly to with poor differentiation < 0.01) was with in this of endometrial carcinoma to cyclophilin A to cyclophilin A of of in a new of endometrial carcinoma to cyclophilin A to cyclophilin A < significant < and < significant < and in a new Of the carcinoma cases for survival analysis and for and and for stages and of cyclophilin A was in in and in The survival to the and survival analysis using suggested that of cyclophilin A was to associated with poor outcome of patients with endometrial carcinoma < The 5-year survival and for and the prognostic of cyclophilin A was of factors associated with outcome of endometrial analysis was using the The cyclophilin A of patients and These factors to significantly the outcome of endometrial carcinoma. A was significant as a prognostic factor in survival of patients of endometrial carcinoma (p < suppression of cyclophilin A expression in cyclophilin cells was RT-PCR that the cyclophilin A expression was by the and Western blot its expression to by inhibition of cyclophilin A expression was by of The of cells was using the and that the was by cyclophilin in and and the was decreased to of the the the and in and the in the cyclophilin was with an inhibition of < data confirmed the of cyclophilin A in endometrial and suppression of cyclophilin A by to a significant in of HEC-1-B growth is to a between and analysis that the in cells in a and the and and the and in and < 0.01) the cell of cyclophilin in an of cell in with a in in a of in and a of in the by cells from apoptosis and a was to the apoptosis by cyclophilin with DNA revealed by and to as by and as in a significant of was in the cyclophilin cells in a < 0.01) compared with the and and These data that inhibition of cyclophilin A expression by to significant apoptosis induction of HEC-1-B cells and in cell in of in over suppression of cyclophilin A in by analysis A for of the or the with or in cyclophilin A expression to with and or of this the of all approximately in significant in tumor growth as by the tumor growth in the of all tumor the in with growth significantly in with for or the of tumor was of the of the tumor in the and for or of tumor in with on over in with < 0.01). These data that cyclophilin A suppression by significantly tumor growth in vivo and with this was that cyclophilin A suppression cell and apoptosis in the in vivo tumor cell and apoptosis by analysis and in of in the for or for the this was on over for with < 0.01). in the to apoptosis in tumor a significantly of with or or < 0.01). significant on or apoptosis among or of cyclophilin A suppression by significantly cell and apoptosis in Endometrial carcinoma one of the of among and the discovery of novel molecular targets for its diagnosis, and the to the and outcome for this disease. the compared the protein between endometrial carcinoma and using a and MS/MS-based approach or the process to of A of 99 differentially expressed proteins identified, most of in including cell protein cell and and that in the and of proteins in and as a of and of on the as multiple with of the for and in carcinoma suggested that the have the of and was to a protein for analysis in for protein of changes of all its of protein between carcinoma and and to have the to and of and and a process with multiple steps of analyses is for proteomics of the 99 proteins with over times as in including cyclophilin protein protein was to in carcinoma with and a of is to in of and gene expression R. R. R. M. M. of proteins in human and cells and Cancer Res. Google Scholar). was as a in to the cancer P. P. M.C. P. expression of the and genes in carcinoma and to human J. Cancer. PubMed Scopus Google Scholar) and in cell cancer J. L. Wang X. F. L. X. M. Z. expression of gene in human cell Cancer Res. Clin. Oncol. 2004; PubMed Scopus Google Scholar). analysis decreased in cancer M. H. H. of cell of markers that of Res. Google Scholar). was to a target of is by P. T. analysis with that genes in cell and S. A. PubMed Scopus Google Scholar). The of and induction expression suggested that via the factor M. R. The the protein 2005; PubMed Scopus Google Scholar). as a target of to the changes carcinogenesis and was to in carcinoma with and a of is a protein as a for protein of cells by R. F. and of a protein by protein J. PubMed Scopus (18) Google Scholar). it is in a it is to in the between to and differentiation S. S. of gene expression in and Res. PubMed Scopus Google Scholar). a proteomics was to in compared with R. of novel in and by PubMed Scopus Google Scholar). the of to its in and cell and differentiation suggest that it in an of the cyclophilin A was characterized as a prognostic biomarker and therapeutic target for endometrial carcinoma on is as in endometrial one of the most significant changes between and carcinoma is by overexpression in carcinoma the of the for and that this is to a common analysis revealed that expression of cyclophilin A was significantly higher in endometrial carcinoma in and its was confirmed by RT-PCR and Western blot analyses. a of the cyclophilin A is an protein with a wide variety of is a and an in protein it was to been to from cells in to J. A is a growth factor by Res. PubMed Scopus Google S. Y. M. proteomics of in vivo tumor of tumor 2006; PubMed Scopus Google Scholar). Many studies have on its in protein and human S. M. of human cyclophilin A to the of Full Text Full Text PDF PubMed Scopus Google Y. Chen Y. M. G. H. A with a of Full Text Full Text PDF PubMed Scopus Google K. G. M. A is for human and the 1999; PubMed Scopus Google S. S. A. A. in the to the cyclophilin A of protein and 4: PubMed Scopus Google of human cells by cyclophilin Biol. PubMed Scopus Google M.A. A. M. A. T. I. F. S. E. J. and from on human interactions with cyclophilin PubMed Scopus Google T. S. of cyclophilin A to of human and PubMed Scopus Google Scholar) and it to the receptor for A. The cyclophilin A the and of factor of cells in and cells Y. Y. A. H. of common of S. A. PubMed Scopus Google L. of human with cyclophilin A and human S. A. PubMed Scopus Google Scholar). overexpression of cyclophilin A was in endometrial studies to there among cyclophilin A expression, and survival as a biomarker for the or of endometrial carcinoma. that overexpression of cyclophilin A was significantly to with a of and survival analysis the correlation of its overexpression with decreased The suggested a of cyclophilin A expression for and as a biomarker for of endometrial carcinoma. Consistent with a in cancer Z. Wang A. E. M.C. G. prognostic of cyclophilin A and factor from protein expression in cell Cancer. 2004; Full Text Full Text PDF PubMed Scopus Google Scholar), significant correlation was between expression of cyclophilin A and and this may have been in to for was that all carcinoma in this with a of stages or cyclophilin that cyclophilin A overexpression in the process of carcinogenesis in advanced or the expression of cyclophilin A in endometrial it have in as a molecular therapeutic Recent studies have cyclophilin A expression in cancer cells and that it a in apoptosis and of of cyclophilin A overexpression been in cancer Wang B. M.C. expression factor and cyclophilin A as molecular targets in cell Res. 2003; Google H. Chen J. J. S. S. L. A is in cell cancer and Res. PubMed Scopus Google Scholar), cancer J. J. Li expression in compared with and by as detected by two-dimensional gel electrophoresis and Res. 2004; PubMed Scopus Google K. Y. S. M. S. M. K. K. I. K. of is in as by by two-dimensional electrophoresis and J. Oncol. Google Scholar), cancer W. G. analysis of Res. PubMed Scopus Google Scholar), and cell carcinoma J. of cell carcinoma: the of multiple in 2004; 4: PubMed Scopus Google Scholar) by proteomics A novel to cyclophilin was to in with overexpression in and cancer A. B. L.H. I. M. M. J. M. S. a novel cyclophilin as a in 21: PubMed Scopus Google Scholar). was the of cyclophilin A overexpression in endometrial and its in carcinogenesis have that inhibition of cyclophilin A in vivo led to cancer growth suppression and cell inhibition R. Z. Wang RNA suppression of cyclophilin A tumor growth in Res. 2005; PubMed Scopus Google Scholar), and cyclophilin A cancer cell growth with and of and protein H. Chen J. J. S. S. L. A is in cell cancer and Res. PubMed Scopus Google M. Wang H. Li F. Chen A is in human cancer cells and cell 2006; PubMed Scopus Google Scholar). Consistent with data that inhibition of cyclophilin A expression led to suppression of cell in vitro as by and a that in cell between cyclophilin A and in various cancer cells J. W. cyclophilin A in cancer cells to and cell Res. PubMed Scopus Google Scholar), and of cyclophilin A in cells on cell growth or J. M. J. and of cyclophilin A is for cell PubMed Scopus Google Scholar). The the of cyclophilin A on cell may on cell or and inhibition is for tumor and to apoptosis induction is a for analysis and that cyclophilin A inhibition significant apoptosis in endometrial carcinoma cells by in cell Consistent with that inhibition of cyclophilin A in vivo led to apoptosis induction in cancer cells that of the R. Z. Wang RNA suppression of cyclophilin A tumor growth in Res. 2005; PubMed Scopus Google Scholar). in the of studies suggested that cyclophilin A cell growth and cell apoptosis in with factor in J. T. A is by a in Res. 2006; PubMed Scopus Google L. Wang M. A is a that Biol. 2004; PubMed Scopus Google N. I. E. E. J. F. G. and cyclophilin A in 2004; PubMed Scopus Google Wang X. J. Z. J. N. M. H. J. G. K. A in the of factor in PubMed Scopus Google Scholar). The between cancer and cells the of cyclophilin A on apoptosis to The data that suppression of cyclophilin A cell and apoptosis in the in vivo the of cyclophilin A suppression on a tumor was with the in suppression of cyclophilin A in vivo was to in decreased tumor growth with inhibition of cell and induction of The the of the of cyclophilin A in vitro and in vivo human endometrial carcinoma. changes in such as or of the in vivo that cyclophilin A suppression by RNA interference to and the there is a that cyclophilin A is a novel therapeutic target endometrial carcinoma. RNA interference in the in with with an attractive approach for is to for tumor growth and by cell survival and Recent studies that cyclophilin A and L. Wang M. A is a that Biol. 2004; PubMed Scopus Google Scholar) and human cell and Y. A as a novel of and J. 2004; Full Text Full Text PDF PubMed Scopus Google Scholar). studies have correlation between and cyclophilin A using RNA interference as by and R. Z. Wang RNA suppression of cyclophilin A tumor growth in Res. 2005; PubMed Scopus Google Scholar). studies to the of cyclophilin A in Recent that of cyclophilin A to apoptosis in cancer cells J. W. cyclophilin A in cancer cells to and cell Res. PubMed Scopus Google L. P. Y. A. E. A. analysis of the to in human cancer Res. 2006; Scopus Google Scholar). an of cyclophilin A A been to in by and apoptosis in cancer cells I. M. J. A. Z. A. B. A and its apoptosis of cells in vitro and in vivo J. Cancer. 2005; PubMed Scopus Google and in 2003; PubMed Scopus Google M.S. A factor of and apoptosis in 2005; PubMed Scopus Google the of to of cyclophilin A using A or novel of cyclophilin A may the of and the of patients with endometrial carcinoma. the the overexpression of cyclophilin A in endometrial carcinoma. of cyclophilin A expression using RNA interference significantly and apoptosis in endometrial carcinoma cells in vitro and in The suggest that cyclophilin A is a novel prognostic factor and possibly a therapeutic target in the of endometrial carcinoma.
60
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Donald Maxwell Parkin, Paola Pisani, Jacques Ferlay · CA A Cancer Journal for Clinicians · 1999 · 3.4K citations · Full text
Hilary A. Coller, Carla Grandori, Pablo Tamayo et al. · Proceedings of the National Academy of Sciences · 2000 · 827 citations
Crystal Structure of Human Cyclophilin A Bound to the Amino-Terminal Domain of HIV-1 Capsid
Theresa Gamble, F.F. Vajdos, Sanghee Yoo et al. · Cell · 1996 · 703 citations · Full text
Cyclophilin A Is a Secreted Growth Factor Induced by Oxidative Stress
Zheng‐Gen Jin, Matthew G. Melaragno, Duan‐Fang Liao et al. · Circulation Research · 2000 · 394 citations · Full text